


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listings of claims

1. (previously presented) A compound of formula (1):



wherein:

A is phenylene ;

n is 0, 1 or 2;

m is 0, 1 or 2;


R^1 is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N,N*-((1-4C)alkyl)₂carbamoyl, sulphonamoyl, *N*-(1-4C)alkylsulphonamoyl, *N,N*-((1-4C)alkyl)₂sulphonamoyl, -S(O)_b(1-4C)alkyl (wherein b is 0, 1, or 2), -OS(O)₂(1-4C)alkyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and -NHSO₂(1-4C)alkyl;

or, when n is 2, the two R^1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring optionally being substituted by one or two methyl groups;

R^4 is independently selected from halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

r is 1 or 2; and

when r is 1 the group



is a substituent on carbon (2) and

when r is 2 (thereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

Y is selected from $-C(O)R^2$, $-C(O)OR^2$, $-C(O)NR^2R^3$, $-(1-4C)alkyl$ [optionally substituted by 1 or 2 substituents independently selected from hydroxy, $-C=NR^2$, $(1-4C)alkoxy$, aryloxy, $-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-O-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-NR^2R^3$, $-N(OH)R^2$, $-NR^2C(=O)R^2$, $-NHOHC(=O)R^2$, $-SO_2NR^2R^3$, $-N(R^2)SO_2R^2$ and aryl], $-C(O)NOH$, $-C(O)NSH$, $-C(N)OH$, $-C(N)SH$, $-SO_2H$, $-SO_3H$, $-SO_2N(OH)R^2$, $-(2-4C)alkenyl$, $-SO_2NR^2R^3$, $-(1-4C)alkylC(O)R^2$, $-(1-4C)alkylC(O)OR^2$, $-(1-4C)alkylSC(O)R^2$, $-(1-4C)alkylOC(O)R^2$, $-(1-4C)alkylC(O)NR^2R^3$, $-(1-4C)alkylOC(O)OR^2$, $-(1-4C)alkylN(R^2)C(O)OR^2$, $-(1-4C)alkylN(R^2)C(O)NR^2R^3$, $-(1-4C)alkylOC(O)NR^2R^3$, $(3-6C)cycloalkyl$ (optionally substituted by 1 or 2 R^8), aryl, $-(1-4C)alkylSO_2(2-4C)alkenyl$ and $-S(O)_cR^2$ (wherein c is 0, 1 or 2);

R^2 and R^3 are independently selected from hydrogen, $-O(1-4C)alkyl$, $-S(1-4C)alkyl$, $-N(1-4C)alkyl$, aryl and $(1-4C)alkyl$ [optionally substituted by 1 or 2 R^8 groups];

R^8 is independently selected from hydrogen, hydroxy, $(1-4C)alkyl$, $(2-4C)alkenyl$, $(1-4C)alkoxy$, cyano $(1-4C)alkyl$, amino $(1-4C)alkyl$ [optionally substituted on nitrogen by 1 or 2 groups selected from $(1-4C)alkyl$, hydroxy, hydroxy $(1-4C)alkyl$, dihydroxy $(1-4C)alkyl$, $-CO_2(1-4C)alkyl$, aryl and aryl $(1-4C)alkyl$], halo $(1-4C)alkyl$, dihalo $(1-4C)alkyl$, trihalo $(1-4C)alkyl$, hydroxy $(1-4C)alkyl$, dihydroxy $(1-4C)alkyl$, $(1-4C)alkoxy(1-4C)alkoxy$, $(1-4C)alkoxy(1-4C)alkyl$, hydroxy $(1-4C)alkoxy$, , aryl, $(3-7C)cycloalkyl$ (optionally substituted with 1 or 2 hydroxy groups, $(1-4C)alkyl$ or $-CO_2(1-4C)alkyl$), $(1-4C)alkanoyl$, $(1-4C)alkylS(O)_b-$ (wherein b is 0, 1 or 2), $(3-6C)cycloalkylS(O)_b-$ (wherein b is 0, 1 or 2), aryl $S(O)_b-$ (wherein b is 0, 1 or 2), benzyl $S(O)_b-$ (wherein b is 0, 1 or 2), $(1-4C)alkylS(O)_c(1-4C)alkyl-$ (wherein c is 0, 1 or 2), $-N(OH)CHO$, $-C(=N-OH)NH_2$, $-C(=N-OH)NH(1-4C)alkyl$, $-C(=N-OH)N((1-4C)alkyl)_2$, $-C(=N-OH)NH(3-6C)cycloalkyl$, $-C(=N-OH)N((3-6C)cycloalkyl)_2$, $-COCOOR^9$, $-C(O)N(R^9)(R^{10})$, $-NHC(O)R^9$, $-C(O)NHSO_2(1-4C)alkyl$, $-NHSO_2R^9$, $(R^9)(R^{10})NSO_2-$, $-COCH_2OR^{11}$, $-COCH_2OH$, $(R^9)(R^{10})N-$, $-COOR^9$, $-CH_2OR^9$, $-CH_2COOR^9$, $-CH_2OCOR^9$, $-CH_2CH(CO_2R^9)OH$, $-CH_2C(O)NR^9R^{10}$, $-(CH_2)_wCH(NR^9R^{10})CO_2R^9$ (wherein w is 1, 2 or 3), and $-(CH_2)_wCH(NR^9R^{10})CO(NR^9R^{10})$ (wherein w is 1, 2 or 3);

R^9 , R^9 , R^{10} and R^{10} are independently selected from hydrogen, hydroxy, $(1-4C)alkyl$ (optionally substituted by 1 or 2 R^{11}), $(2-4C)alkenyl$, $(3-7C)cycloalkyl$ (optionally substituted by 1 or 2 hydroxy groups), cyano $(1-4C)alkyl$, trihalo $(1-4C)alkyl$, aryl, $-CO_2(1-4C)alkyl$;

R^{11} is independently selected from $(1-4C)alkyl$, and hydroxy $(1-4C)alkyl$;

or a pharmaceutically acceptable salt thereof.

2. (cancelled).

3. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein n is 0.

4 (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein r is 1.

5. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein m is 1.

6. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein Y is selected from $-C(O)OR^2$, $-C(O)NR^2R^3$, $-(1-4C)alkyl$ [optionally substituted by a substituent selected from hydroxy, (1-4C)alkoxy, $-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-O-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-NR^2R^3$, $-NR^2C(=O)R^2$ and $-SO_2NR^2R^3$], $-(1-4C)alkylC(O)R^2$, $-(1-4C)alkylC(O)OR^2$, $-(1-4C)alkylOC(O)R^2$, $-(1-4C)alkylC(O)NR^2R^3$, $-(1-4C)alkylOC(O)OR^2$, $-(1-4C)alkylN(R^2)C(O)OR^2$, $-(1-4C)alkylN(R^2)C(O)NR^2R^3$, $-(1-4C)alkylSC(O)R^2$, $-(1-4C)alkylOC(O)NR^2R^3$, $-(1-4C)alkylSO_2(2-4C)alkenyl$ and $-SO_cR^2$ (wherein c is 0, 1 or 2).

7. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R^2 and R^3 are independently selected from hydrogen, , $-O(1-4C)alkyl$, $-N(1-4C)alkyl$, (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups];

8. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R^8 is independently selected from hydrogen, hydroxy, $-C(O)N(R^9)(R^{10})$, $-NHC(O)R^9$, $-COOR^9$, $-CH_2OR^9$, $-CH_2COOR^9$, $-CH_2OCOR^9$ and aryl.


9. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl).

10. (previously presented) A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.


11-15 (cancelled)

16. (withdrawn) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:

reacting an acid of the formula (2):



or an activated derivative thereof; with an amine of formula (3):



and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

17. (previously presented) A compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R^4 is selected from chloro, fluoro and methyl.

18. (currently amended) A compound of the ~~formula (1)~~ formula (1) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein

A is phenylene;

n is 0;

m is 1;

R^4 is chloro;

Y is selected from $-C(O)OR^2$, $-C(O)NR^2R^3$, $-(1-4C)alkyl$ [optionally substituted by a substituent selected from $-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-O-S(O)_bR^2$ (wherein b is 0, 1 or 2), $-NR^2R^3$, $-NR^2C(=O)R^2$ and $-SO_2NR^2R^3$], $-(1-4C)alkylC(O)OR^2$, $-(1-4C)alkylOC(O)R^2$, $-(1-4C)alkylC(O)NR^2R^3$, $-(1-4C)alkylSC(O)R^2$, $-(1-4C)alkylSO_2(2-4C)alkenyl$ and $-SO_cR^2$ (wherein c is 0, 1 or 2);

R^2 and R^3 are independently selected from hydrogen, and (1-4C)alkyl [optionally substituted by 1 or 2 R^8 groups]
 R^8 is independently selected from hydrogen, hydroxy, $-C(O)N(R^9)(R^{10})$, $-NHC(O)R^9$, $-COOR^9$ and aryl;

R^9 and R^{10} are independently selected from hydrogen, hydroxy and (1-4C)alkyl.

19. (currently amended) A compound of the ~~formula (4)~~ formula (1) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, selected from

Methyl (1*R*,2*R*)-2-[[*(*5-chloro-1*H*-indole-2-yl)carbonyl]amino]indane-1-carboxylate;

5-Chloro-*N*-[(1*R*,2*R*)-1-(hydroxymethyl)-2,3-dihydro-1*H*-inden-2-yl]-indole-2-carboxamide;
 (1*R*,2*R*)-2-[[*(*5-chloro-1*H*-indole-2-yl)carbonyl]amino]indane-1-carboxylic acid;

5-Fluoro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;

N-[(1*R*,2*R*)-1-({[(2-Hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-5-methyl-1*H*-indole-2-carboxamide;

N-[(1*R*,2*R*)-1-({[(2-Hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;

5-Chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)amino]sulfonyl}methyl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;

5-Fluoro-*N*-((1*R*,2*R*)-1-{{[(3-hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-{{[(3-Hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-5-methyl-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-{{[(3-Hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

5-Chloro-*N*-((1*R*,2*R*)-1-{{[(3-hydroxypropyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

[[*(*(1*R*,2*R*)-2-{{[(5-Chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetic acid;

Methyl [[*(*(1*R*,2*R*)-2-{{[(5-chloro-1*H*-indol-2-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)thio]acetate;

5-Fluoro-*N*-((1*R*,2*R*)-1-{{[(2-hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide ;

5-Chloro-*N*-((1*R*,2*R*)-1-{{[(2-hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-{{[(2-Hydroxyethyl)sulfonyl]methyl}-2,3-dihydro-1*H*-inden-2-yl)-5-methyl-1*H*-indole-2-carboxamide;

N-((1*R*,2*R*)-1-[(2-Hydroxyethyl)sulfonyl]methyl)-2,3-dihydro-1*H*-inden-2-yl)-1*H*-indole-2-carboxamide; and

N-{(1*R*,2*R*)-1-[(2-Amino-2-oxoethyl)thio]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide.

20. (withdrawn) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

21. (currently amended) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

22. (currently amended) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.